Cholecalciferol_67-97-0_DataSheet_MedChemExpress

合集下载

阿昔洛韦杂质列表-标准品

阿昔洛韦杂质——孟成科技（上海）有限公司名称信息结构式阿昔洛韦杂质Acyclovir Impurity分子式/Molecular Formula ：C10H13N5O4分子量/Molecular Weight ：267.24CAS#:102728-64-3阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C5H5N5O分子量/Molecular Weight ：151.13CAS#:73-40-5阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C8H11N5O3分子量/Molecular Weight ：225.2CAS#:91702-61-3阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C14H16N10O4分子量/Molecular Weight ：388.34CAS#:166762-90-9阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C17H22N10O6分子量/Molecular Weight ：462.42CAS#:1797131-64-6阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C12H15N5O5分子量/Molecular Weight ：309.28CAS#:91702-60-2阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C7H9N5O2分子量/Molecular Weight ：195.18CAS#:23169-33-7阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C8H11N5O3分子量/Molecular Weight ：225.21阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C9H13N5O4分子量/Molecular Weight ：255.24阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C17H22N10O6分子量/Molecular Weight ：462.43阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C9H13N5O4分子量/Molecular Weight ：255.24阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C12H15N5O5分子量/Molecular Weight ：309.28CAS#:75128-73-3阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C9H9N5O3分子量/Molecular Weight ：235.2CAS#:3056-33-5阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C10H13N5O4分子量/Molecular Weight ：267.24CAS#:110104-37-5阿昔洛韦杂质Acyclovir Impurity 分子式/Molecular Formula ：C14H16N10O4分子量/Molecular Weight ：388.34CAS#:1797832-75-7。

Roche MagNA Lyser 产品说明书

Ordering Information Cat. No. Product ***********MagNA Lyser Instrument (230 Volt)***********MagNA Lyser Instrument (110 Volt)(Instruments supplied with rotor and rotor cooling block)***********MagNA Lyser Green Beads (100 tubes)Related Products Cat. No. Product***********MagNA Pure LC DNA Isolation Kit II (Tissue)***********MagNA Pure LC mRNA Isolation Kit II (Tissue)03 330 591 001MagNA Pure LC RNA Isolation Kit III (Tissue)***********MagNA Pure LC DNA Isolation Kit III (Bacteria, Fungi)***********MagNA Pure LC RNA Isolation Tissue Lysis Buffer – Refill (70 ml)System DescriptionHomogenize up to 16 samples in just a few seconds.Save valuable lab space with a small benchtop instrument.Reduce hands-on time by replacing the mortar and pestle and other manual methods.Integrate your workflow with the automated nucleic acid isolation of the MagNA Pure LC Instrument.Perform consistent and reproducible sample disruption.Process many different sample types.Prevent nucleic acid degradation with the benchtop cooling unit.Ease your setup with a removable rotor and prefilled disposable vials.Automate with an easy-to-use instrumentVersatile, efficient, and rapid pre-preparationFigure 71. Add your sample and lysis buffer to the MagNA Lyser Green Beads.2. Homogenize with the MagNA Lyser Instrument.3. Centrifuge to pellet the debris.4. Proceeed with the supernatant to prepare nucleic acids or proteins.For detailed information,visit or contact your local representative.Trademarks:MagNA Pure, MagNA Lyser, LightCycler, and the MagNA Pure Logo are trademarks of a member of the Roche Group.The technology used for the LightCycler System is licensed from Idaho Technology Inc., Salt Lake City, UT, USA.Fully automated sample preparationon the PCR Workflow SystemRoche Diagnostics GmbH Roche Applied Science Nonnenwald 282372 Penzberg Germany0000Roche Applied Science Part of Roche DiagnosticsMagNA Lyser InstrumentStart the Ball Rollingwith Automated Tissue HomogenizationᕤᕣᕢᕡFigure 6Components of the system.The MagNA Lyser InstrumentAutomated tissue homogenizationProcessing conditionsRefer to the following tables for guidelines on setting up your homogenizationSample material(10 mg)*Time settings(seconds)Cooling(between the runs)Speed Average yield(µg)***Average purity(OD 280/260 nm)***Spleen 2 x 25 906,00030–40 1.9Liver 25-6,00016–18 1.8Lung 2 x 25906,00025 1.8Kidney25-6,000201.8Maize leaves **20-5,00010n.d.Maize polenta **20-5,0008n.d.Tortilla chips **20-5,0001n.d.*Aliqout containing 10 mg sample material (here mouse and food samples) was taken for the DNA purificationusing the MagNA Pure LC DNA Isolation Kit II (Tissue), (see pack insert)**Centrifugation after the homogenization for 5 minutes at 2,200 x g*** Yield and purity strongly depend on the condition of the sample material n.d.not determinedData kindly provided by Dr. Peterhänsel, RWTH Aachen, GermanyFigure 1Gel electrophoresis from genomic DNA isolated from tissue homogenized with the MagNA LyserInstrument, using the MagNA Pure LC DNA Kit II (Tissue).Marker: DNA Marker III*Aliquot containing 10 mg sample material (here mouse and human research samples) was taken to purify RNAeither with the MagNA Pure LC RNA Isolation Kit III (Tissue) or the MagNA Pure LC mRNA Isolation Kit II (Tissue) homogenized with the MagNA Lyser Instrument.** Yield and purity strongly depend on the condition of the sample material. The yield for mRNA was not determined.Sample material(10 mg)*Time settings(cycles/seconds)Cooling(between/afterthe runs in seconds)SpeedAverage yield (mg)(total RNA)**Average purity(OD 280/260 nm)**RNA/mRNARarely expressed targets in small numbers of target cells,as seen in experiments about minimalresidual diseases,are difficult to detect.Increasing the cell number can improve sensitivity and lead to accurate results.Without the MagNA Lyser pre-processing,the MagNA Pure mRNA HS Kit can efficiently obtain mRNA from a maximum of 1 x 107white blood cells (WBCs),as shown in research studies with human samples.However,using greater cell numbers results in a saturation effect with quantitative assays (Figure 3).Homogenization of the lysate with the MagNA Lyser Instrument prior to the purification eliminatesthe amplification saturation at 1 x 107cells and allows the use of up to 2.5 x 107WBCs (Figure 4 and 5),enhancing the analytical sensitivity of the assay.Eliminate sensitivity barriers with increased sample inputFigure 3mRNA was purified from different amounts of human white blood cells with the MagNA Pure mRNA HS Kit. G6PDH was amplified using the LightCycler t(9;22) Quantification Kit (see text beside).Figure 4mRNA was purified from different amounts of human white blood cells with the MagNA Pure mRNA HS Kit. The lysates from 2.5 x 107cells and 5 x 107cells were homogenized with the MagNA Lyser Instrument (2x50 seconds with 90 seconds cooling in between) prior to the mRNA purification. G6PDH was amplified using the LightCycler t(9;22) Quantification Kit (see text beside).Figure 5Scalability from 1 x 106cells to 2.5 x 107cells is represented in the graph and the table of the relationship between crossing points and cell numbers. The limitation of cell input is indicated by no change in crossing point with increased cell number (see text beside).Cell number 5 x 1072.5 x 1071 x 1075 x 1061 x 106Log (cell number)7.77.47.06.76.0Crossing point 20.320.321.822.424.4crossingpointLog(cell number)252423222120195.86.36.87.37.8Figure 2Gel electrophoresis from total RNA isolated from tissue homogenized with the MagNA Lyser Instrument, using the MagNA Pure LC RNA Kit III (Tissue).Ma r k e rS p l e e nL i v e rL u n gK i d n e yM a r k e rMa i z e l e a v e sMa i z e l e a v e sS p l e e nL i v e r11 kb5 kb5 kb28 S rRNA 18 S rRNASpleen 2 x 50 90 6,500–7,000 30–40 1.9Liver 50 - 6,500–7,000 13–17 2.0Thymoid tissue60906,500n.d.n.d.Heart 60 90 6,500 n.d. n.d.Abdominal fat 60 90 6,500 n.d. n.d.Aorta 60 90 6,500 n.d. n.d. Other samples1+n x 50 90 6,500–7,000- -1 x 105 x 101 x 10- 5 x 101 x 105 x 105 x 10- 5 x 102.5 x 10 5 x 10。

分子生物学词汇(中英文对照表 )

稳定性英文版

HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFLUOXETINE HClC17H18F3NO•HClM.W. = 345.79CAS — 59333-67-4STABILITY INDICATINGA S S A Y V A L I D A T I O NMethod is suitable for:ýIn-process controlþProduct ReleaseþStability indicating analysis (Suitability - US/EU Product) CAUTIONFLUOXETINE HYDROCHLORIDE IS A HAZARDOUS CHEMICAL AND SHOULD BE HANDLED ONLY UNDER CONDITIONS SUITABLE FOR HAZARDOUS WORK.IT IS HIGHLY PRESSURE SENSITIVE AND ADEQUATE PRECAUTIONS SHOULD BE TAKEN TO AVOID ANY MECHANICAL FORCE (SUCH AS GRINDING, CRUSHING, ETC.) ON THE POWDER.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationTABLE OF CONTENTS INTRODUCTION........................................................................................................................ PRECISION............................................................................................................................... System Repeatability ................................................................................................................ Method Repeatability................................................................................................................. Intermediate Precision .............................................................................................................. LINEARITY................................................................................................................................ RANGE...................................................................................................................................... ACCURACY............................................................................................................................... Accuracy of Standard Injections................................................................................................ Accuracy of the Drug Product.................................................................................................... VALIDATION OF FLUOXETINE HCl AT LOW CONCENTRATION........................................... Linearity at Low Concentrations................................................................................................. Accuracy of Fluoxetine HCl at Low Concentration..................................................................... System Repeatability................................................................................................................. Quantitation Limit....................................................................................................................... Detection Limit........................................................................................................................... VALIDATION FOR META-FLUOXETINE HCl (POSSIBLE IMPURITIES).................................. Meta-Fluoxetine HCl linearity at 0.05% - 1.0%........................................................................... Detection Limit for Fluoxetine HCl.............................................................................................. Quantitation Limit for Meta Fluoxetine HCl................................................................................ Accuracy for Meta-Fluoxetine HCl ............................................................................................ Method Repeatability for Meta-Fluoxetine HCl........................................................................... Intermediate Precision for Meta-Fluoxetine HCl......................................................................... SPECIFICITY - STABILITY INDICATING EVALUATION OF THE METHOD............................. FORCED DEGRADATION OF FINISHED PRODUCT AND STANDARD..................................1. Unstressed analysis...............................................................................................................2. Acid Hydrolysis stressed analysis..........................................................................................3. Base hydrolysis stressed analysis.........................................................................................4. Oxidation stressed analysis...................................................................................................5. Sunlight stressed analysis.....................................................................................................6. Heat of solution stressed analysis.........................................................................................7. Heat of powder stressed analysis.......................................................................................... System Suitability stressed analysis.......................................................................................... Placebo...................................................................................................................................... STABILITY OF STANDARD AND SAMPLE SOLUTIONS......................................................... Standard Solution...................................................................................................................... Sample Solutions....................................................................................................................... ROBUSTNESS.......................................................................................................................... Extraction................................................................................................................................... Factorial Design......................................................................................................................... CONCLUSION...........................................................................................................................ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationBACKGROUNDTherapeutically, Fluoxetine hydrochloride is a classified as a selective serotonin-reuptake inhibitor. Effectively used for the treatment of various depressions. Fluoxetine hydrochloride has been shown to have comparable efficacy to tricyclic antidepressants but with fewer anticholinergic side effects. The patent expiry becomes effective in 2001 (US). INTRODUCTIONFluoxetine capsules were prepared in two dosage strengths: 10mg and 20mg dosage strengths with the same capsule weight. The formulas are essentially similar and geometrically equivalent with the same ingredients and proportions. Minor changes in non-active proportions account for the change in active ingredient amounts from the 10 and 20 mg strength.The following validation, for the method SI-IAG-206-02 , includes assay and determination of Meta-Fluoxetine by HPLC, is based on the analytical method validation SI-IAG-209-06. Currently the method is the in-house method performed for Stability Studies. The Validation was performed on the 20mg dosage samples, IAG-21-001 and IAG-21-002.In the forced degradation studies, the two placebo samples were also used. PRECISIONSYSTEM REPEATABILITYFive replicate injections of the standard solution at the concentration of 0.4242mg/mL as described in method SI-IAG-206-02 were made and the relative standard deviation (RSD) of the peak areas was calculated.SAMPLE PEAK AREA#15390#25406#35405#45405#55406Average5402.7SD 6.1% RSD0.1ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::PRECISION - Method RepeatabilityThe full HPLC method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method repeated six times and the relative standard deviation (RSD) was calculated.SAMPLENumber%ASSAYof labeled amountI 96.9II 97.8III 98.2IV 97.4V 97.7VI 98.5(%) Average97.7SD 0.6(%) RSD0.6PRECISION - Intermediate PrecisionThe full method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method was repeated six times by a second analyst on a different day using a different HPLC instrument. The average assay and the relative standard deviation (RSD) were calculated.SAMPLENumber% ASSAYof labeled amountI 98.3II 96.3III 94.6IV 96.3V 97.8VI 93.3Average (%)96.1SD 2.0RSD (%)2.1The difference between the average results of method repeatability and the intermediate precision is 1.7%.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationLINEARITYStandard solutions were prepared at 50% to 200% of the nominal concentration required by the assay procedure. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over the concentration range required. Y-Intercept was found to be insignificant.RANGEDifferent concentrations of the sample (IAG-21-001) for the 20mg dosage form were prepared, covering between 50% - 200% of the nominal weight of the sample.Conc. (%)Conc. (mg/mL)Peak Area% Assayof labeled amount500.20116235096.7700.27935334099.21000.39734463296.61500.64480757797.52000.79448939497.9(%) Average97.6SD 1.0(%) RSD 1.0ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::RANGE (cont.)The results demonstrate linearity as well over the specified range.Correlation coefficient (RSQ)0.99981 Slope11808.3Y -Interceptresponse at 100%* 100 (%) 0.3%ACCURACYACCURACY OF STANDARD INJECTIONSFive (5) replicate injections of the working standard solution at concentration of 0.4242mg/mL, as described in method SI-IAG-206-02 were made.INJECTIONNO.PEAK AREA%ACCURACYI 539299.7II 540599.9III 540499.9IV 5406100.0V 5407100.0Average 5402.899.9%SD 6.10.1RSD, (%)0.10.1The percent deviation from the true value wasdetermined from the linear regression lineHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::ACCURACY OF THE DRUG PRODUCTAdmixtures of non-actives (placebo, batch IAG-21-001 ) with Fluoxetine HCl were prepared at the same proportion as in a capsule (70%-180% of the nominal concentration).Three preparations were made for each concentration and the recovery was calculated.Conc.(%)Placebo Wt.(mg)Fluoxetine HCl Wt.(mg)Peak Area%Accuracy Average (%)70%7079.477.843465102.27079.687.873427100.77079.618.013465100.0101.0100%10079.6211.25476397.910080.8011.42491799.610079.6011.42485498.398.6130%13079.7214.90640599.413080.3114.75632899.213081.3314.766402100.399.618079.9920.10863699.318079.3820.45879499.418080.0820.32874899.599.4Placebo, Batch Lot IAG-21-001HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION OF FLUOXETINE HClAT LOW CONCENTRATIONLINEARITY AT LOW CONCENTRATIONSStandard solution of Fluoxetine were prepared at approximately 0.02%-1.0% of the working concentration required by the method SI-IAG-206-02. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over this range.ACCURACY OF FLUOXETINE HCl AT LOW CONCENTRATIONThe peak areas of the standard solution at the working concentration were measured and the percent deviation from the true value, as determined from the linear regression was calculated.SAMPLECONC.µg/100mLAREA FOUND%ACCURACYI 470.56258499.7II 470.56359098.1III 470.561585101.3IV 470.561940100.7V 470.56252599.8VI 470.56271599.5(%) AverageSlope = 132.7395299.9SD Y-Intercept = -65.872371.1(%) RSD1.1HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSystem RepeatabilitySix replicate injections of standard solution at 0.02% and 0.05% of working concentration as described in method SI-IAG-206-02 were made and the relative standard deviation was calculated.SAMPLE FLUOXETINE HCl AREA0.02%0.05%I10173623II11503731III10103475IV10623390V10393315VI10953235Average10623462RSD, (%) 5.0 5.4Quantitation Limit - QLThe quantitation limit ( QL) was established by determining the minimum level at which the analyte was quantified. The quantitation limit for Fluoxetine HCl is 0.02% of the working standard concentration with resulting RSD (for six injections) of 5.0%. Detection Limit - DLThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected. The detection limit of Fluoxetine HCl is about 0.01% of the working standard concentration.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION FOR META-FLUOXETINE HCl(EVALUATING POSSIBLE IMPURITIES)Meta-Fluoxetine HCl linearity at 0.05% - 1.0%Relative Response Factor (F)Relative response factor for Meta-Fluoxetine HCl was determined as slope of Fluoxetine HCl divided by the slope of Meta-Fluoxetine HCl from the linearity graphs (analysed at the same time).F =132.7395274.859534= 1.8Detection Limit (DL) for Fluoxetine HClThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected.Detection limit for Meta Fluoxetine HCl is about 0.02%.Quantitation Limit (QL) for Meta-Fluoxetine HClThe QL is determined by the analysis of samples with known concentration of Meta-Fluoxetine HCl and by establishing the minimum level at which the Meta-Fluoxetine HCl can be quantified with acceptable accuracy and precision.Six individual preparations of standard and placebo spiked with Meta-Fluoxetine HCl solution to give solution with 0.05% of Meta Fluoxetine HCl, were injected into the HPLC and the recovery was calculated.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES].Approx.Conc.(%)Known Conc.(µg/100ml)Area in SpikedSampleFound Conc.(µg/100mL)Recovery (%)0.0521.783326125.735118.10.0521.783326825.821118.50.0521.783292021.55799.00.0521.783324125.490117.00.0521.783287220.96996.30.0521.783328526.030119.5(%) AVERAGE111.4SD The recovery result of 6 samples is between 80%-120%.10.7(%) RSDQL for Meta Fluoxetine HCl is 0.05%.9.6Accuracy for Meta Fluoxetine HClDetermination of Accuracy for Meta-Fluoxetine HCl impurity was assessed using triplicate samples (of the drug product) spiked with known quantities of Meta Fluoxetine HCl impurity at three concentrations levels (namely 80%, 100% and 120% of the specified limit - 0.05%).The results are within specifications:For 0.4% and 0.5% recovery of 85% -115%For 0.6% recovery of 90%-110%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES]Approx.Conc.(%)Known Conc.(µg/100mL)Area in spikedSample Found Conc.(µg/100mL)Recovery (%)[0.4%]0.4174.2614283182.66104.820.4174.2614606187.11107.370.4174.2614351183.59105.36[0.5%]0.5217.8317344224.85103.220.5217.8316713216.1599.230.5217.8317341224.81103.20[0.6%]0.6261.3918367238.9591.420.6261.3920606269.81103.220.6261.3920237264.73101.28RECOVERY DATA DETERMINED IN SPIKED SAMPLESHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::REPEATABILITYMethod Repeatability - Meta Fluoxetine HClThe full method (as described in SI-IAG-206-02) was carried out on the finished drug product representing lot number IAG-21-001-(1). The HPLC method repeated serially, six times and the relative standard deviation (RSD) was calculated.IAG-21-001 20mg CAPSULES - FLUOXETINESample% Meta Fluoxetine % Meta-Fluoxetine 1 in Spiked Solution10.0260.09520.0270.08630.0320.07740.0300.07450.0240.09060.0280.063AVERAGE (%)0.0280.081SD 0.0030.012RSD, (%)10.314.51NOTE :All results are less than QL (0.05%) therefore spiked samples with 0.05% Meta Fluoxetine HCl were injected.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::Intermediate Precision - Meta-Fluoxetine HClThe full method as described in SI-IAG-206-02 was applied on the finished product IAG-21-001-(1) .It was repeated six times, with a different analyst on a different day using a different HPLC instrument.The difference between the average results obtained by the method repeatability and the intermediate precision was less than 30.0%, (11.4% for Meta-Fluoxetine HCl as is and 28.5% for spiked solution).IAG-21-001 20mg - CAPSULES FLUOXETINESample N o:Percentage Meta-fluoxetine% Meta-fluoxetine 1 in spiked solution10.0260.06920.0270.05730.0120.06140.0210.05850.0360.05560.0270.079(%) AVERAGE0.0250.063SD 0.0080.009(%) RSD31.514.51NOTE:All results obtained were well below the QL (0.05%) thus spiked samples slightly greater than 0.05% Meta-Fluoxetine HCl were injected. The RSD at the QL of the spiked solution was 14.5%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSPECIFICITY - STABILITY INDICATING EVALUATIONDemonstration of the Stability Indicating parameters of the HPLC assay method [SI-IAG-206-02] for Fluoxetine 10 & 20mg capsules, a suitable photo-diode array detector was incorporated utilizing a commercial chromatography software managing system2, and applied to analyze a range of stressed samples of the finished drug product.GLOSSARY of PEAK PURITY RESULT NOTATION (as reported2):Purity Angle-is a measure of spectral non-homogeneity across a peak, i.e. the weighed average of all spectral contrast angles calculated by comparing all spectra in the integrated peak against the peak apex spectrum.Purity Threshold-is the sum of noise angle3 and solvent angle4. It is the limit of detection of shape differences between two spectra.Match Angle-is a comparison of the spectrum at the peak apex against a library spectrum.Match Threshold-is the sum of the match noise angle3 and match solvent angle4.3Noise Angle-is a measure of spectral non-homogeneity caused by system noise.4Solvent Angle-is a measure of spectral non-homogeneity caused by solvent composition.OVERVIEWT he assay of the main peak in each stressed solution is calculated according to the assay method SI-IAG-206-02, against the Standard Solution, injected on the same day.I f the Purity Angle is smaller than the Purity Threshold and the Match Angle is smaller than the Match Threshold, no significant differences between spectra can be detected. As a result no spectroscopic evidence for co-elution is evident and the peak is considered to be pure.T he stressed condition study indicated that the Fluoxetine peak is free from any appreciable degradation interference under the stressed conditions tested. Observed degradation products peaks were well separated from the main peak.1® PDA-996 Waters™ ; 2[Millennium 2010]ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFORCED DEGRADATION OF FINISHED PRODUCT & STANDARD 1.UNSTRESSED SAMPLE1.1.Sample IAG-21-001 (2) (20mg/capsule) was prepared as stated in SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 98.5%.SAMPLE - UNSTRESSEDFluoxetine:Purity Angle:0.075Match Angle:0.407Purity Threshold:0.142Match Threshold:0.4251.2.Standard solution was prepared as stated in method SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 100.0%.Fluoxetine:Purity Angle:0.078Match Angle:0.379Purity Threshold:0.146Match Threshold:0.4272.ACID HYDROLYSIS2.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of conc. HCl was added to this solution The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system after filtration.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 98.8%.SAMPLE- ACID HYDROLYSISFluoxetine peak:Purity Angle:0.055Match Angle:0.143Purity Threshold:0.096Match Threshold:0.3712.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask. 20mL Diluent were added. 2mL of conc. HCl were added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 97.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSTANDARD - ACID HYDROLYSISFluoxetine peak:Purity Angle:0.060Match Angle:0.060Purity Threshold:0.099Match Threshold:0.3713.BASE HYDROLYSIS3.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weight into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 99.3%.SAMPLE - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.063Match Angle:0.065Purity Threshold:0.099Match Threshold:0.3623.2.Standard stock solution was prepared as per method SI-IAG-206-02 : About 22mg Fluoxetine HCl was weighed into a 50mL volumetric flask. 20mL Diluent was added. 2mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH=5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease - 99.5%.STANDARD - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.081Match Angle:0.096Purity Threshold:0.103Match Threshold:0.3634.OXIDATION4.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02. An equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent added and the solution sonicated for 10 minutes.1.0mL of 30% H2O2 was added to the solution and allowed to stand for 5 hours, then made up to volume with Diluent, filtered and injected into HPLC system.Fluoxetine peak intensity decreased to 95.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSAMPLE - OXIDATIONFluoxetine peak:Purity Angle:0.090Match Angle:0.400Purity Threshold:0.154Match Threshold:0.4294.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask and 25mL Diluent were added. 2mL of 30% H2O2 were added to this solution which was standing for 5 hours, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity decreased to 95.8%.STANDARD - OXIDATIONFluoxetine peak:Purity Angle:0.083Match Angle:0.416Purity Threshold:0.153Match Threshold:0.4295.SUNLIGHT5.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1hour. The BST was set to 35°C and the ACT was 45°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak decreased to 91.2% and the dark control solution showed assay of 97.0%. The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak was observed at RRT of 1.5 (2.7%).The total percent of Fluoxetine peak with the degradation peak is about 93.9%.SAMPLE - SUNLIGHTFluoxetine peak:Purity Angle:0.093Match Angle:0.583Purity Threshold:0.148Match Threshold:0.825 ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSUNLIGHT (Cont.)5.2.Working standard solution was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1.5 hour. The BST was set to 35°C and the ACT was 42°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak was decreased to 95.2% and the dark control solution showed assay of 99.5%.The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak were observed at RRT of 1.5 (2.3).The total percent of Fluoxetine peak with the degradation peak is about 97.5%. STANDARD - SUNLIGHTFluoxetine peak:Purity Angle:0.067Match Angle:0.389Purity Threshold:0.134Match Threshold:0.8196.HEAT OF SOLUTION6.1.Sample solution of IAG-21-001-(2) (20 mg/capsule) was prepared as in method SI-IAG-206-02 . Equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution was sonicated for 10 minutes and made up to volume with Diluent. 4mL solution was transferred into a suitable crucible, heated at 105°C in an oven for 2 hours. The sample was cooled to ambient temperature, filtered and injected into the HPLC system.Fluoxetine peak was decreased to 93.3%.SAMPLE - HEAT OF SOLUTION [105o C]Fluoxetine peak:Purity Angle:0.062Match Angle:0.460Purity Threshold:0.131Match Threshold:0.8186.2.Standard Working Solution (WS) was prepared under method SI-IAG-206-02 . 4mL of the working solution was transferred into a suitable crucible, placed in an oven at 105°C for 2 hours, cooled to ambient temperature and injected into the HPLC system.Fluoxetine peak intensity did not decrease - 100.5%.ED. N0: 04Effective Date:APPROVED::。

芦荟苷 2

芦荟苷资源科学与工程1101 刘贺11740106 芦荟苷其中大多为双子叶植物百合科植物库拉索芦荟、好望角芦荟、斑纹芦荟提取物。

芦荟苷的分子结构式，芦荟苷的物理性质是黄色或淡黄色结晶粉末。

熔点:148～149oC(乙醇)，一水合物熔点70～80。

[αc]D+21°(水),[α]D-8.3°。

略带沉香气味,味苦,易溶于吡啶,溶于冰醋酸,甲酸,丙酮,醋酸甲酯,以及乙醇等，1份溶解于130份，芦荟苷的化学性质对分别从中华芦荟、库拉索芦荟和木立芦荟叶肉组织中分离提取得到的3种凝集素(命名为Lec1、Lec2和Lec3)进行了理化性质的比较研究,考察了三者的分子质量,对糖抑制的专一性和糖基组成.结果表明Lec1和Lec3的相对分子质量为23 000,而Lec2为26 000 ,只有Lec3能被麦芽糖抑制.糖基组成分析结果表明,三者的糖链部分主要由甘露糖、葡萄糖和N-乙酰氨基葡萄糖构成.三种芦荟凝集素能够识别并抑制K562乳腺癌细胞的生长,中华凝集素、库拉索凝集素、木立凝集素的抑瘤率IC50值分别为4.193 、2.305 、1.418 mg/ml.而在质量浓度>2.5 mg/ml时他们对成纤维细胞FC的生长有定的促进作用.动物体内实验进一步证实了芦荟凝集素的抑瘤作用,同时表明芦荟凝集素能够激发机体的免疫功能来抵御癌细胞的入侵.其中芦荟苷对人体是有利的，然而芦荟中含有大量活性物质，若用传统热提取技术，很容易破坏其功能性成分，影响产品品质。

采用膜分离技术可以把芦荟生物活性物质以不同的分子量区段进行分离，并且可有效澄清芦荟产品，可有效保留其功能性成分，保护产品功效。

然而对于芦荟苷的提取和精制大概包括下面的几个步骤芦荟鲜叶→清洗、消毒、去边角→打浆→胶体磨→离心过滤→贮罐→灭菌→原汁→脱色→微滤→超滤→反渗透→芦荟多糖溶液→浓缩渣→酶解→提取芦荟甙溶液→精制→芦荟甙，芦荟苷粗制将风干后的芦荟粉末，加氯仿回流充分提取2小时，振摇，趁热过滤，除去苷元及其他游离蒽醌衍生物，残渣于表面皿风干，以除去剩余=的氯仿。

癸氧喹酯美国药典

高效液相色谱法测定癸氧喹酯溶液的含量癸氧喹酯（Decoquinate）是一种喹啉类抗球虫药，不但对球虫的子孢子和滋养体有强烈的抑制作用，而且对发育中的第一代裂殖体有杀灭作用，对卵囊的孢子化过程亦有抑制作用[1]。

该药自从1967年上市以来，一直被许多国家用于预防肉仔鸡的球虫病[2]。

美国雅来大药厂在我国最先注册了该产品的预混剂，其抗球虫作用与药物颗粒大小有关，颗粒愈细，抗球虫作用愈强，因此宜制成直径1.8 μm左右的微粒供临床使用。

癸氧喹酯溶液是青岛六和药业有限公司研制的抗球虫药，为了制定其科学合理的质量控制方法，建立了癸氧喹酯溶液含量测定的高效液相色谱法，方法简便快捷，重现性好，灵敏度高，可为完善该制剂的质量标准提供有价值的参考。

1 仪器与试药Agilent 1100 高效液相色谱仪,包括DAD检测器、自动进样系统和Agilent ChemStation色谱工作站；电子分析天平AG285。

癸氧喹酯溶液，含量规格100mL：3.0g，青岛六和药业有限公司研制；癸氧喹酯标准品，含量99.90%，购自美国对照品标准委员会；甲醇、乙腈均为色谱纯试剂；二氯甲烷、硝酸钙、冰醋酸、三乙胺均为分析纯；水为重蒸馏水。

2 方法与结果2.1 溶剂的配制取硝酸钙10g，置烧杯中，加无水甲醇143mL溶解，再加入二氯甲烷143mL，用无水甲醇稀释至1000mL，混匀，即得二氯甲烷-无水甲醇（1：6）溶液。

2.2 供试品溶液的制备照相对密度测定法[3]，测定癸氧喹酯溶液的密度。

精密称取本品适量（约含癸氧喹酯为25mg）置于50mL容量瓶，用2.1所述溶剂稀释至刻度，摇匀，再从此溶液中精密吸取10mL置于100mL容量瓶，用溶剂稀释到刻度，作为供试品溶液（浓度50µg/mL）。

2.3 对照品溶液的制备精密称取约25mg癸氧喹酯对照品置于50mL量瓶中，加入约15mL溶剂，加热使溶解，再用溶剂稀释至刻度，摇匀，再从此溶液中精密吸取10mL至100mL量瓶中，用2.1所述溶剂稀释至刻度，作为对照品溶液（浓度50µg/mL）。

格锐思可溶性糖含量试剂盒说明书 (货号：G0501W 微板法 96 样)

可溶性糖含量试剂盒说明书(货号：G0501W微板法96样）一、产品简介：糖类物质是构成植物体的重要组成成分之一，也是新陈代谢的主要原料和贮存物质。

糖类在浓硫酸作用下经脱水反应生成糠醛或羟甲基糖醛，生成的糠醛或羟甲基糖醛与蒽酮脱水缩合，形成糠醛的衍生物，呈蓝绿色物质，其在可见光区620nm波长处有最大吸收，且其光吸收值在一定范围内与糖的含量成正比关系。

该方法用于可溶性单糖、寡糖和多糖的含量测定，具有灵敏度高﹑简便快捷﹑适用于微量样品的测定等优点。

该方法的特点是几乎可以测定所有的糖类（包括单糖：戊糖、己糖、糖原、多缩葡萄糖等），所以用该方法测出的糖类含量是溶液中全部可溶性糖类总含量。

二、试剂盒组分与配制：试剂名称规格保存要求备注试剂一粉剂×1瓶4℃避光保存试剂二液体5mL×1瓶4℃保存标准品粉剂×1支4℃保存若重新做标曲，则用到该试剂工作液配制：吸取4mL试剂二加入到试剂一的试剂瓶中，混匀并充分溶解，即得工作液。

（如难溶解，可60℃水浴溶解；剩余试剂4℃保存一周）三、所需的仪器和用品：酶标仪、96孔板、水浴锅、可调式移液器、乙醇、浓硫酸（不允许快递）、研钵。

四、可溶性糖含量的测定：建议正式实验前选取2个样本做预测定，了解本批样品情况，熟悉实验流程，避免实验样本和试剂浪费！建议：选取样本做几个梯度的稀释，选取适合本次实验的稀释倍数D。

1组织样本：称取0.1g样本（若是干样，如烘干烟叶等可取0.05g；若是水分充足的样本可取0.2g），先加入0.8mL的80%乙醇（自备：取80mL乙醇溶于20mL蒸馏水中），冰浴匀浆，倒入有盖离心管中，再用80%乙醇冲洗研钵并转移至同一EP管中，使EP管中粗提液终体积定容为1.5mL（若用自动研磨机可直接加入1.5mL的80%乙醇研磨）；置50℃水浴20min（封口膜缠紧，防止液体散失，且间隔2min振荡混匀一次），冷却后（若有损失，可加80%乙醇补齐至1.5mL），12000rpm，室温离心10min，取上清液备用。

1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐标准物质

1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐标准物质
1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐（EDC.HCl）是一种白色结晶粉末，分子式为C8H17N3.HCl，分子量为191.7。

它的反应靶标是活化羧基与氨基（伯胺）偶联，可以用于多种偶联策略，例如将EDC单独与靶标基团反应，或包括NHS或磺基-NHS，以提高反应效率或稳定活性中间体，用于后续胺类反应。

EDC.HCl已用于多种应用，如在肽合成中形成酰胺键、连接半抗原与载体蛋白形成免疫原、通过5'磷酸基标记核酸以及构建生物分子的胺反应性NHS酯。

如需了解更多关于EDC.HCl标准物质的信息，可以访问国家标准物质网或咨询专业化学试剂供应商。

细胞角蛋白(广谱)抗体试剂(免疫组织化学)说明书

【注意事项】
1. 供专业人员使用。 2. 该产品中含有叠氮钠 (NaN3)，纯品具有高度的化学毒性。产品中叠氮钠的浓度虽然不能被认定为危险
性浓度，但是叠氮钠可以与铅、铜发生化学反应，形成具有爆炸性危险的叠氮化金属物质。处理时需要用大量清水冲洗，防止管道中形成金属叠氮化物质。 3. 与所有生物来源的产品相同，必须遵循相关操作步骤。 4. 穿戴合适的个人防护装置，避免皮肤和眼睛接触。 5. 请按照当地、地区以及国家的相关法规，处理未使用的溶液。
【主要组成成份】
1．提供的试剂即用型单克隆小鼠抗体以液体形式提供，缓冲液中含有稳定蛋白和0.015 mol/L NaN3。克隆：AE1/AE3 同型：IgG1，kappa 2．免疫原人体表皮细胞愈伤组织 (1)。 3．特异性 AE1/AE3 包括两种单克隆抗体，采用人愈伤组织细胞角蛋白免疫小鼠的方法得到 (2)。研究显示， AE1/AE3 能够识别大部分人细胞角蛋白，因此可以作为 IHC 中单层和复层上皮来源的判定工具 (1,2,4)。抗体 AE1 能够与大部分亚组 A 细胞角蛋白的抗原决定簇发生反应，包括 Moll 分型(4) 中的 10、13、14、 15、16 和 19（分子量分别为 56.5、54'、50、50'、48 和 40 kDa），但是不包括编号为 12、17 和 18（分子量分别为 55、47 和 45 kDa）的细胞角蛋白(4)。抗体 AE3 能够与亚组 B 细胞角蛋白的抗原决定簇发生反应，包括编号为 1 和 2、3、4、5、6、7 和 8（分子量分别为 65、67、64、59、58、56、54 和 52 kDa）的细胞角蛋白(5)。
5. Eichner R, Bonitz P, Sun T-T. Classification of epidermal keratins according to their immunoreactivity, isoelectric point and mode of expression. J Cell Biol 1984; 98:1388

Sigma-Aldrich实验室常用生化试剂大促销

缓冲液
产品货号英文品名中文品名优惠价 (R M B ) 目录价 (RMB)
A1542-2.5KG A1542-250G A1542-500G B7901-1KG B7901-500G C3041-100CAP C3041-50CAP C3674-100G C3674-1KG C3674-500G E9508-100ML E9508-10UL E9508-1L E9508-2.5L E9508-500ML E6758-100G E6758-500G H3375-100G H3375-1KG H3375-250G H3375-25G H3375-500G H3375-5KG I0125-100G I0125-10G I0125-1KG I0125-25G I0125-500G I0125-5KG M2933-100G M2933-1KG M2933-25G M2933-500G M1254-100G M1254-1KG M1254-250G M1254-25G M1254-50KG M1254-5KG P5493-1L P5493-4L P4809-100TAB P4809-50TAB
Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose
低熔点琼脂糖低熔点琼脂糖低熔点琼脂糖低熔点琼脂糖低熔点琼脂糖低熔点琼脂糖琼脂糖琼脂糖琼脂糖琼脂糖琼脂糖琼脂糖
Ammonium acetate ~98% Ammonium acetate ~98% Ammonium acetate ~98% Boric acid Boric acid Carbonate-Bicarbonate Buffer Carbonate-Bicarbonate Buffer Citric acid trisodium salt Citric acid trisodium salt Citric acid trisodium salt Ethanolamine >=98% Ethanolamine >=98% Ethanolamine >=98% Ethanolamine >=98% Ethanolamine >=98% Ethylenediaminetetraacetic acid >=98.5% Ethylenediaminetetraacetic acid >=98.5% HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) MES hydrate >=99.5% MES hydrate >=99.5% MES hydrate >=99.5% MES hydrate >=99.5% MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) Phosphate buffered saline Phosphate buffered saline Phosphate-Citrate Buffer Phosphate-Citrate Buffer

枸杞PPT课件

枸杞子亦为扶正固本，生精补髓、滋阴补肾、益气安神、强身健体、延缓衰老之良药，对慢性肝炎、中心性视网膜炎、视神经萎缩等疗效显著；对糖尿病、肺结核等也有较好疗效；对抗肿瘤、保肝、降压、降血糖以及老年人器官衰退的老化疾病都有很强的改善作用。作为滋补强壮剂治疗肾虚各症及肝肾疾病疗效甚佳，能显著提高人体中血浆睾酮素含量，达到强身之功效。现代医学研究表明，枸杞对体外癌细胞有明显的抑制作用，可用于防止癌细胞的扩散和增强人体的免疫功能.
而言，初无分别也，后世以枸杞子为滋补药，地骨皮为退热
药，始分而二之。窃谓枸杞苗叶，味苦甘而气凉，根味甘淡
气寒，子味甘气平，气味既殊，则功用当别，此后人发前人
未到之处者也。《保寿堂方》载地仙丹云：此药性平，常服
能除邪热，明目轻身。春采枸杞叶，名天精草；夏采花，名
长生草；秋采子，名枸杞子；冬采根，名地骨皮；并阴干，
喜光照。对土壤要求不严，耐盐碱、耐肥、耐旱、怕水渍。以肥沃、排水良好的中性或微酸性轻壤土栽培为宜，盐碱土的含盐量不能超过0.2%，在强碱性、粘壤土、水稻田、沼泽地区不宜栽培。
形态特征多分枝灌木，高0.5-1米，栽培时可达2米多；枝条细弱，
弓状弯曲或俯垂，淡灰色，有纵条纹，棘刺长0.5-2厘米，生叶和花的棘刺较长，小枝顶端锐尖成棘刺状。叶纸质或栽培者质稍厚，单叶互生或2-4枚簇生，卵形、卵状菱形、长椭圆形、卵状披针形，顶端急尖，基部楔形，长1.5-5 厘米，宽0.5-2.5厘米，栽培者较大，可长达10厘米以上，宽达4厘米；叶柄长0.4-1厘米。花在长枝上单生或双生于叶腋，在短枝上则同叶簇生；花梗长1-2厘米，向顶端渐增粗。花萼长3-4毫米，通常3中裂或4-5齿裂，裂片多少有缘毛；花冠漏斗状，长9-12毫米，淡紫色，筒部向上骤然扩大，稍短于或近等于檐部裂片，5深裂，裂片卵形，顶端圆钝，平展或稍向外反曲，边缘有缘毛，基部耳显著；雄蕊较花冠稍短，或因花冠裂片外展而伸出花冠，花丝在近基部处密生一圈绒毛并交织成椭圆状的毛丛，与毛丛等高处的花冠筒内壁亦密生一环绒毛；花柱稍伸出雄蕊，上端弓弯，柱头绿色。浆果红色，卵状，栽培者可成长矩圆状或长椭圆状，顶端尖或钝，长7-15毫米，栽培者长可达 2.2厘米，直径5-8毫米。种子扁肾脏形，长2.5-3毫米，黄色。花果期6-11月。

酪氨酸

本品为白色结晶或结晶性粉末；无臭，无味。本品在水中极微溶解，在无水乙醇、甲醇或丙酮中不溶；在稀盐酸或稀硝酸中溶解。
取本品，精密称定，加1mol/L盐酸溶液溶解并定量稀释制成每1ml中约含50mg的溶液，依法测定（2010年版药典二部附录ⅥE），比旋度为-11.3°至-12.1° 。
（1）取本品与酪氨酸对照品各适量，分别加稀氨溶液（浓氨溶液14→100）溶解并稀释制成每1ml中约含 0.4mg的溶液，作为供试品溶液与对照品溶液。照其他氨基酸项下的色谱条件试验，供试品溶液所显主斑点的位置和颜色应与对照品溶液的主斑点相同。
2.以酪蛋白为原料，盐酸中回流数小时，过滤、浓缩后，碱中和、活性炭处理、结晶得产品。
3.由干酪素或绢丝等蛋白质的酸水解物经中和产生的沉淀分离后，溶于稀氨水，用醋酸中和至PH值为5时进行重结晶而得。
4.L-酪氨酸的制备主要是采取蛋白质水解提取法。可用猪血粉、角蹄、蚕丝等原料，经酸水解，再分离纯化。
猪血粉[HCl(水解)]→[110℃, 24h]水解液[赶酸]→[蒸发浓缩]除酸液[活性炭]→脱色液[脱色，冷却结晶]→L-酪氨酸粗品[活性炭（精制）]→[90℃, 30min]滤液[结晶]→L-酪氨酸。
（2）本品的红外光吸收图谱应与对照的图谱（《药品红外光谱集》1072图）一致。
1、酸度取本品0.02g，加水100ml制成饱和水溶液，依法测定（2010年版药典二部附录Ⅵ H），pH值应为5.0～6.5。 2、溶液的透光率取本品1.0g，加1mol/L盐酸溶液20ml溶解后，照紫外－可见分光光度法（2010年版药典二部附录ⅣA），在 430nm的波长处测定透光率，不得低于95.0%。 3、氯化物取本品0.25g，依法检查（2010年版药典二部附录ⅧA），与标准氯化钠溶液5.0ml制成的对照液比较，不得更浓（0.02%）。 4、硫酸盐取本品1.0g，加水40ml温热使溶解，放冷，依法检查（2010年版药典二部附录Ⅷ B），与标准硫酸钾溶液 2.0ml同法制成的对照液比较，不得更浓（0.02%）。

lip e

lip脂肪酶脂肪酶脂肪酶脂肪酶脂肪酶脂肪酶脂肪酶脂肪酶比色法比色法比色法比色法液体试剂液体试剂液体试剂液体试剂lipasecolometricassay组成组成组成组成7020706071507170缓冲液缓冲液缓冲液缓冲液coliposae胆酸盐胆酸盐胆酸盐胆酸盐664ml乳胶乳胶乳胶乳胶色素低物色素低物色素低物色素低物胆酸盐胆酸盐胆酸盐胆酸盐619298871929895缓冲液缓冲液缓冲液缓冲液coliposae胆酸盐胆酸盐胆酸盐胆酸盐6180ml乳胶乳胶乳胶乳胶色素低物色素低物色素低物色素低物胆酸盐胆酸盐胆酸盐胆酸盐6缓冲液缓冲液缓冲液缓冲液coliposae胆酸盐胆酸盐胆酸盐胆酸盐1240ml乳胶乳胶乳胶乳胶色素低物色素低物色素低物色素低物胆酸盐胆酸盐胆酸盐胆酸盐6
LIP 脂肪酶
标本收集及准备用标准样品管收集血清。肝素的锂、钠、铵盐的抗凝血浆。稳定性：20～25℃稳定 7 天
4～8 ℃稳定 7 天－20℃稳定 1 年 EDTA、草酸、氟化物或柠檬酸的抗凝血浆使脂肪酶结果偏低（抑制脂肪酶活力）。在检测前应离心去除沉淀。
检测程序提供的材料： - 如上所述的应用试剂要求增加的材料： - 校准品和控制品 - 0.9% NaCl - 一般实验室设备
计算罗氏 /日立系统自动地计算出各样品内的脂肪酶活力。
干扰判断指标：回收率在初始值的±10%内，干扰属可接受。为了避免脂肪酶检测和甘油三酯、胆固醇、 HDL-C 直接法、LDL-C 直接法、钙等项目同时检测时反应杯与与样品探针的交叉污染；请使用 SMS 的回避软件。黄疸：I 指数低于 60（结合胆红素和游离胆红素浓度约为 1026µmol/L）没有明显干扰。溶血：H 指数低于 500（血红蛋白浓度约为 5 g/L）没有明显干扰。脂血（内脂）：L 指数低于 1000（甘油三酯浓度约为 22.6 mmol/L）没有明显干扰。但是脂血混浊的浊度和甘油三酯间相关性很差。

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

References: [1]. Leibowitz SB, Kantoff PW. Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands. Semin Oncol. 2003 Oct;30(5):698-708. [2]. [ ] Di Rosa M, Malaguarnera g M, Nicoletti F, Malaguarnera g L. Vitamin D3: a helpful p immunomodulator. Immunology. 2011 Oct;134(2):123-39. doi: 10.1111/j.1365-2567.2011.03482.x. [3]. Krishnan AV, Feldman D. Mechanisms of the anti-cations of vitamin D. Annu Rev Pharmacol Toxicol. 2011;51:311-36. doi: 10.1146/annurev-pharmtox-010510100611. [4]. Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis. 2012 Jul;60(1):139-56. doi: 10.1053/j.ajkd.2011.12.035.
Product Data Sheet
Product Name: CAS No.: Cat. No.: MWt: Formula: Purity :
Cholecalciferol 67-97-0 HY-15398 384.64 C27H44O >98%
Solubility:
DMSO
Mechanisms: Pathways:Vitamin D Related; Target:VD/VDR g y Biological Activity: Cholecalciferol(Vitamin D3) is a naturally occuring form of vitamin D; Reported that upon metabolic activation, Cholecalciferol induces cell differentiation and prevents proliferation of cancer cells. IC50 value: Target: Vitamin D acts through a receptor that is a member of the ligand-dependent transcription factor superfamily. Modulates the proliferation and differentiation of both normal and cancer cells. Has antiproliferative and antimetastatic effects on breast, colon, and prostate cancer cells. Activated vitamin D receptors p in intestine and bone maintain calcium absorbance and homeostasis....
Caution: Not fully tested. For research purposes only Medchemexpress LLC

m o c . s s e r p x e m e h c d e m . w w w : b e AW Sm Uo ,c 0 4. 5s 8s 0e r p Jx Ne ,m n e oh t c e cd ne i rm P @ ,o y f an Wi : l ni oa sm n iE k l i W 8 1